Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Voyager Therapeutics (VYGR) EPS (Basic): 2014-2024

Historic EPS (Basic) for Voyager Therapeutics (VYGR) over the last 11 years, with Dec 2024 value amounting to -$1.13.

  • Voyager Therapeutics' EPS (Basic) fell 193.75% to -$0.47 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.17, marking a year-over-year decrease of 414.49%. This contributed to the annual value of -$1.13 for FY2024, which is 136.69% down from last year.
  • As of FY2024, Voyager Therapeutics' EPS (Basic) stood at -$1.13, which was down 136.69% from $3.08 recorded in FY2023.
  • In the past 5 years, Voyager Therapeutics' EPS (Basic) registered a high of $3.08 during FY2023, and its lowest value of -$1.89 during FY2021.
  • Over the past 3 years, Voyager Therapeutics' median EPS (Basic) value was -$1.13 (recorded in 2024), while the average stood at $0.25.
  • Per our database at Business Quant, Voyager Therapeutics' EPS (Basic) slumped by 290.91% in 2021 and then surged by 354.55% in 2023.
  • Voyager Therapeutics' EPS (Basic) (Yearly) stood at $0.99 in 2020, then plummeted by 290.91% to -$1.89 in 2021, then soared by 35.98% to -$1.21 in 2022, then spiked by 354.55% to $3.08 in 2023, then plummeted by 136.69% to -$1.13 in 2024.